sefulness of I-FABP in the diagnosis and follow-up of celiac disease.
Recruiting
- Conditions
- celiac disease, I-FABP, diagnosis, non-invasive, human leukocyte antigen (HLA)
- Registration Number
- NL-OMON23786
- Lead Sponsor
- Maastricht University Medical Center (MUMC), Nutrition and Toxicology Research Institute Maastricht (NUTRIM)
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 225
Inclusion Criteria
1. Clinical suspicion of celiac disease and/or positive celiac disease screening (tissue transglutaminase (tTG), endomysium (EMA) or gliadine (AGA) antibodies);
2. Age between 6 months and 18 years.
Exclusion Criteria
History of inflammatory bowel disease.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The usefulness of I-FABP plasma levels for diagnosing celiac disease in children with enhanced titres of tTG, EMA or AGA antibodies and genetic predisposition.
- Secondary Outcome Measures
Name Time Method 1. Value of recovery of I-FABP levels in response to a gluten-free diet;<br /><br>2. Value of urine I-FABP levels.